Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ainos, Inc. - warrants (NQ:AIMDW)

0.1230 +0.0280 (+29.47%)
Streaming Delayed Price Updated: 2:28 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ainos, Inc. - warrants

< Previous 1 2 3 4 Next >
News headline image
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
Via ACCESSWIRE
News headline image
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
Via ACCESSWIRE
News headline image
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
Via ACCESSWIRE
News headline image
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Via ACCESSWIRE
News headline image
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
Via ACCESSWIRE
News headline image
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
News headline image
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
Via ACCESSWIRE
News headline image
Ainos Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
Ainos Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
Via ACCESSWIRE
News headline image
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
Via ACCESSWIRE
News headline image
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Via ACCESSWIRE
News headline image
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
Via ACCESSWIRE
News headline image
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
Via ACCESSWIRE
News headline image
Ainos Reports Full Year 2023 Financial Results
Via ACCESSWIRE
News headline image
Ainos Announces $1.75 Million Follow-On Funding
Via ACCESSWIRE
News headline image
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
Via ACCESSWIRE
News headline image
Ainos Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Via ACCESSWIRE
News headline image
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Via ACCESSWIRE
News headline image
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
News headline image
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Via ACCESSWIRE
News headline image
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
Via ACCESSWIRE
News headline image
Ainos Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Ainos Celebrates First Listing Anniversary on Nasdaq
Via ACCESSWIRE
News headline image
Ainos, Inc. Announces Stock Consolidation
Via ACCESSWIRE
News headline image
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Via ACCESSWIRE
News headline image
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
Via ACCESSWIRE
News headline image
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.